Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Androsterone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 6/20 | 0.90 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.90 |
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.90 |
| ▸ | MEN1 | O00255 | 3/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.90 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.90 |
| ▸ | SHBG | P04278 | 2/20 | 0.90 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.90 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.90 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.90 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.90 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.90 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.90 |
| ▸ | TSHR | P16473 | 1/20 | 0.90 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Androsterone SCHEMBL17165679 | 1.00 | G6PD (0.90) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL17165674 | 1.00 | G6PD (0.90) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL136325 | 1.00 | G6PD (0.90) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL7989333 | 0.99 | G6PD (0.88) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL1570817 | 0.99 | G6PD (0.88) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL7996607 | 0.99 | G6PD (0.88) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL23031469 | 0.95 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL19750468 | 0.95 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL269982 | 0.95 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 | |
| Androsterone SCHEMBL15426610 | 0.95 | G6PD (1.00) | G6PDGPBAR1LMNACYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250199014-A1 | METABOLITE BIOMARKERS FOR DISEASES ASSOCIATED WITH THE CONTACT ACTIVATION SYSTEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-06-19 | — | — | US | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| CN-115128257-B | Metabolism marker for predicting liver cancer incidence risk and application thereof | 南京医科大学 | 2025-02-18 | — | — | CN | claimed |
| CN-113396332-B | Method for evaluating pregnancy progression and premature abortion for clinical intervention and use thereof | 斯坦福大学托管董事会 | 2025-02-11 | — | — | CN | claimed |
| US-12188948-B2 | Metabolite biomarkers for diseases associated with the contact activation system | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | claimed |
| US-20240358719-A1 | Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-10-31 | — | — | US | claimed |
| EP-4313061-A1 | FORMULATIONS FOR PROLONGING GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION | The Board of Trustees of the Leland Stanford Junior University (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117202910-A | Formulations for prolonging pregnancy and for menstruation or pregnancy complications | 斯坦福大学托管董事会 | 2023-12-08 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-109716137-B | Metabolite biomarkers for diseases associated with contact activation systems | 武田药品工业株式会社 | 2023-07-21 | — | — | CN | claimed |
| US-20100273207-A1 | Methods for Diagnosis of Sepsis and Risk of Death | LANGLEY RAYMOND | 2010-10-28 | — | — | US | claimed |
| WO-2010124269-A1 | METHODS FOR DIAGNOSIS OF SEPSIS AND RISK OF DEATH | NATIONAL CENTER FOR GENOME RESOURCES (US) | 2010-10-28 | — | — | WO | claimed |
| JP-4313435-B2 | — | — | 2009-08-12 | — | — | JP | claimed |
| US-6083941-A | TREATMENT OF NEUROPATHIC PAIN, DRUG WITHDRAWAL/DEPENDENCY, EPILEPSY, GLAUCOMA, CHRONIC NEURODEGENERATIVE DISEASES, AMYOTROPHIC LATERAL SCLEROSIS, ANXIETY DISORDERS, BRAIN CELL DEATH, ISCHAEMIA, STROKE, TRAUMA | TRUSTEES OF BOSTON UNIVERSITY (US) | 2000-07-04 | — | — | US | claimed |
| US-5888996-A | ANTICONVULSANTS | TRUSTEES OF BOSTON UNIVERSITY (US) | 1999-03-30 | — | — | US | claimed |
| EP-0840612-A1 | INHIBITION OF NMDA RECEPTOR ACTIVITY BY PREGNENOLONE SULFATE DERIVATIVES | TRUSTEES OF BOSTON UNIVERSITY (US) | 1998-05-13 | — | — | EP | claimed |
| WO-1997003677-A1 | INHIBITION OF NMDA RECEPTOR ACTIVITY BY PREGNENOLONE SULFATE DERIVATIVES | TRUSTEES OF BOSTON UNIVERSITY (US) | 1997-02-06 | — | — | WO | claimed |
| US-5155045-A | Altering or regulating length of menstrual cycle by exposing nasal region of female to component of axillary secretions of male | TRUSTEES OF THE UNIVERSITY OF PENN. (US) | 1992-10-13 | — | — | US | claimed |
| EP-0209590-A1 | THE USE OF MALE ESSENCE, INCLUDING ANDROSTENOL AND DEHYDROEPIANDROSTERONE SULFATE TO TREAT LUTEAL PHASE DEFECTS AND FAILURE TO OVULATE IN HUMAN FEMALES | MONELL CHEMICAL SENSES CENTER (US) | 1987-01-28 | — | — | EP | claimed |
| WO-1986004236-A1 | THE USE OF MALE ESSENCE, INCLUDING ANDROSTENOL AND DEHYDROEPIANDROSTERONE SULFATE TO TREAT LUTEAL PHASE DEFECTS AND FAILURE TO OVULATE IN HUMAN FEMALES | MONELL CHEMICAL SENSES CENTER (US) | 1986-07-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358719-A1 | Formulations for Prolonging Gestation and for Complications of Menstruation or Gestation | PGF, GNRHR, PTGDR | G6PD 695/4885GPBAR1 145/4885LMNA 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.